<DOC>
	<DOCNO>NCT01122342</DOCNO>
	<brief_summary>Atrophic vaginitis condition skin line vagina labia becomes thin symptom develop include vaginal itching , vaginal discomfort dyspareunia . These significantly affect woman 's comfort , sexuality quality life . Treatment condition include estrogen give pill form , commonly know hormone replacement therapy local estrogen treatment , vaginal estrogen cream topical vaginal lubricant . Unfortunately , systemic estrogen contraindicate many woman breast cancer . Some provider also feel woman take aromatase inhibitor breast cancer also use local estrogen several small study suggest treatment might effect estrogen level thus might change effective aromatase inhibitor . If woman choose use form estrogen therapy symptom may well control treatment . The investigator hypothesize vaginal testosterone cream might safe effective alternative treatment woman . This small study intend test hypothesis testosterone cream increase estrogen ( estradiol ) level improve symptom atrophic vaginitis include vaginal dryness , vaginal itching pain intercourse . The investigator enroll woman trial take aromatase inhibitor symptom mention . They receive testosterone cream apply vaginally day 28 day . If good result find prespecified dose testosterone , low dose test next group woman enrol .</brief_summary>
	<brief_title>Vaginal Testosterone Cream For Atrophic Vaginitis Women Taking Aromatase Inhibitors Breast Cancer .</brief_title>
	<detailed_description>Atrophic vaginitis condition skin line vagina labia becomes thin , usually due decrease estrogen state - menopause . Symptoms atrophic vaginitis include vaginal itching , vaginal discomfort dyspareunia significantly affect woman 's comfort , sexuality quality life . Treatment condition include estrogen give pill form , commonly know hormone replacement therapy local estrogen treatment , vaginal estrogen cream topical vaginal lubricant . Unfortunately , systemic estrogen contraindicate many woman breast cancer . Some provider also feel woman take aromatase inhibitor breast cancer also use local estrogen several small study suggest treatment might effect estrogen level thus might change effective aromatase inhibitor . If woman choose use form estrogen therapy symptom may well control treatment . The investigator hypothesize vaginal testosterone cream might safe effective alternative treatment woman . This small study intend test hypothesis testosterone cream increase estrogen ( estradiol ) level improve symptom atrophic vaginitis include vaginal dryness , vaginal itching pain intercourse . The investigator enroll woman trial take aromatase inhibitor symptom mention . They receive testosterone cream apply vaginally day 28 day . If good result find prespecified dose testosterone , low dose test next group woman enrol . Objectives : PRIMARY OBJECTIVE : 1.1 . Does topical testosterone cream affect serum estradiol level woman take aromatase inhibitor breast cancer ? SECONDARY OBJECTIVES : 1.2 . Can atrophic vaginitis resultant symptom vaginal dryness , itch dyspareunia woman take aromatase inhibitor treatment breast cancer improve topical testosterone cream ? 1.3 . Does topical testosterone cream affect physical finding , pH cytologic change atrophic vaginitis ? Schema : Intervention - Subjects apply testosterone cream vaginal area daily one month ( 28 day ) . Evaluation - Before study intervention participant testosterone high-sensitivity estradiol test . They complete questionnaire symptom atrophic vaginitis gynecologic examination ( visual , speculum , pH sample vaginal epithelial cell . ) Endpoints - Serum estradiol level Improvement symptom atrophic vaginitis , measure questionnaire . Atrophic vaginitis measure gynecological examination ( include pH cytology ass maturation index ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer ( stage ) . Currently use aromatase inhibitor ( anastrazole , exemestane letrozole ) primary adjuvant breast cancer treatment . Must complaint vaginal itching , vaginal dryness and/or dyspareunia . Not undergo active chemotherapeutic radiotherapeutic treatment Age &gt; 18 year Life expectancy great 2 month . CALGB ( ZUBROD ) performance status &lt; 3 . Postmenopausal define absence menses least 12 month and/or FSH &gt; 25 . Not postmenopausal function medication intend suppress ovarian function , gonadotropin release hormone agonist . Surgically postmenopausal subject eligible . The effect topical testosterone cream develop human fetus recommend therapeutic dose unknown . For study postmenopausal woman include woman childbearing potential exclude . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Patients recover adverse event due chemotherapeutic agent administer 4 week earlier . History allergic reaction attribute compound similar chemical biologic composition testosterone emollient delivery cream use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman woman breastfeed exclude study limit postmenopausal woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Vaginal administration</keyword>
	<keyword>Aromatase inhibitor</keyword>
</DOC>